Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/heartjnl-2012-303082 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Which is the most cost-effective antiseizure medication for initial monotherapy for focal epilepsy?
Epilepsia
January 2025
Department of Pharmacy, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Objective: An increasing number of antiseizure medications (ASMs) are approved for monotherapy for focal epilepsy, but direct comparisons of the lifetime cost-effectiveness of all existing treatment strategies are lacking. This study aims to compare the cost-effectiveness of new ASMs and traditional ASMs as first-line monotherapy for newly diagnosed focal epilepsy.
Method: We used a Markov model to evaluate the lifetime cost-effectiveness of 10 ASMs in the treatment of focal epilepsy, with lacosamide (LCM) as a control, from the perspective of society in the United States.
The multifaceted role of XCL1 in health and disease.
Protein Sci
February 2025
Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, Queensland, Australia.
The chemokine XC motif chemokine ligand 1 (XCL1) is an unusually specialized member of a conserved family of around 50 small, secreted proteins that are best known for their ability to stimulate the directional migration of cells. All chemokines adopt a very similar folded structure that binds a specific G protein-coupled receptor (GPCR), and most chemokines bind extracellular matrix glycosaminoglycans, often in a dimeric or oligomeric form. Owing in part to the lack of a disulfide bond that is conserved in all other chemokines, XCL1 interconverts between two distinct structures with distinct functions.
View Article and Find Full Text PDFEthics of Procuring and Using Organs or Tissue from Infants and Newborns for Transplantation, Research, or Commercial Purposes: Protocol for a Bioethics Scoping Review.
Wellcome Open Res
December 2024
National University of Singapore, Singapore, Singapore.
Unlabelled: Since the inception of transplantation, it has been crucial to ensure that organ or tissue donations are made with valid informed consent to avoid concerns about coercion or exploitation. This issue is particularly challenging when it comes to infants and younger children, insofar as they are unable to provide consent. Despite their vulnerability, infants' organs and tissues are considered valuable for biomedical purposes due to their size and unique properties.
View Article and Find Full Text PDFEfficient and accurate variational inference for multilevel threshold autoregressive models in intensive longitudinal data.
Br J Math Stat Psychol
January 2025
Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Recent technological advancements have enabled the collection of intensive longitudinal data (ILD), consisting of repeated measurements from the same individual. The threshold autoregressive (TAR) model is often used to capture the dynamic outcome process in ILD, with autoregressive parameters varying based on outcome variable levels. For ILD from multiple individuals, multilevel TAR (ML-TAR) models have been proposed, with Bayesian approaches typically used for parameter estimation.
View Article and Find Full Text PDFFinal Analysis of Post-Marketing Surveillance for Avelumab + Axitinib in Patients With Renal Cell Carcinoma in Japan.
Cancer Med
January 2025
Department of Urology, Keio University School of Medicine, Tokyo, Japan.
Introduction: Avelumab, an anti-programmed death ligand 1 antibody, was approved in combination with axitinib for curatively unresectable or metastatic renal cell carcinoma (RCC) in Japan in December 2019. Because the pivotal JAVELIN Renal 101 study included a limited number of Japanese patients, post-marketing surveillance (PMS) was required to evaluate outcomes (safety and effectiveness) in patients with RCC who received avelumab + axitinib treatment in clinical practice in Japan.
Materials And Methods: We report data from prospective, noncomparative, multicenter, observational PMS in patients with RCC who received ≥ 1 dose of avelumab.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!